<DOC>
	<DOCNO>NCT01373138</DOCNO>
	<brief_summary>This open label randomise , 2-way crossover , comparative bioequivalence study .</brief_summary>
	<brief_title>Bioequivalence Study Desloratadine Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions</brief_title>
	<detailed_description>The objective study compare rate extent absorption Dr. Reddy 's Laboratories Ltd. , India , desloratadine-pseudoephedrine Schering Corporation , U.S.A. ( Clarinex-D® 24-HOUR ) , desloratadine-pseudoephedrine , administer 1 x 5 mg/240 mg extended-release tablet fast condition . The treatment phase separate washout period 14 day . 34 subject ( 19 male 15 female ) dose enrol study ; 31 enrol subject complete study .</detailed_description>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<criteria>Male female , nonsmoker , ≥18 ≤45 year age . Capable consent . Medically healthy clinically normal laboratory profile , vital sign ECG . BMI ≥19.0 ≤30.0 . Clinically significant illness surgery within 4 week prior dose . Any clinically significant abnormality abnormal laboratory test result find medical screening . Any reason , opinion Medical SubInvestigator , would prevent subject participate study . Positive test hepatitis B , hepatitis C , HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . History significant alcohol abuse drug abuse within one year prior screen visit . Regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) . Use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction desloratadine , pseudoephedrine relate drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior dose . Clinically significant history presence gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g.diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant history presence neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption hormonal contraceptive . Difficulty swallow study medication . Use tobacco product 3 month precede drug administration . Any food allergy , intolerance , restriction special diet , opinion Medical SubInvestigator , could contraindicate subject 's participation study . ● A depot injection implant drug ( hormonal contraceptive ) within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 499 mL whole blood within 30 day , 499 mL whole blood within 56 day prior drug administration . Hemoglobin low 140g/L male 125 g/L female . History known presence narrowangle glaucoma , urinary retention , renal impairment , coronary artery ischemic heart disease , diabetes mellitus , prostatic hypertrophy hyperthyroidism . Positive urine pregnancy test screening . Breastfeeding subject . Female subject childbearing potential unprotected sexual intercourse nonsterile male partner ( i.e . male sterilized vasectomy least 6 month ) within 14 day prior study drug administration . Acceptable method contraception : intrauterine contraceptive device ( place least 4 week prior study drug administration ; condom diaphragm + spermicide ; hormonal contraceptive ( start least 4 week prior study drug administration ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Desloratadine pseudoephedrine</keyword>
	<keyword>crossover</keyword>
</DOC>